Specialty code 1835P2201X · Sacramento, CA
NPI
1992252803
Since 2016
Specialty
Specialty code 1835P2201X
Code 1835P2201X
Group practices
0
Medicare group memberships
Hospitals
0
Hospital affiliations
4301 X St
Sacramento, CA, 95817
Phone (916) 734-2011
Medicare paid
-
No Medicare services published
Medicare patients
-
Drug cost, 2024
$516K
3,382 prescriptions
Company payments
-
None reported
Medicare prescription drug claims, 2024
In 2024, the drug Derek N Fong prescribed most often to Medicare patients was Atorvastatin Calcium, with 469 prescriptions and refills. In total Derek N Fong wrote 3,382 Medicare prescriptions that cost $516K.
| Drug |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-08-22.
| Claims |
|---|
| 30-day fills |
|---|
| Patients |
|---|
| Cost |
|---|
| Atorvastatin Calcium Generic | 469 | 1,547 | 176 | $5,734 |
| Ozempic Semaglutide | 323 | 338 | 54 | $239K |
| Metformin Hcl Er Metformin Hcl | 315 | 1,024 | 133 | $3,052 |
| Metformin Hcl Generic | 218 | 726 | 77 | $3,105 |
| Jardiance Empagliflozin | 178 | 529 | 70 | $94K |
| Glipizide Er Glipizide | 167 | 552 | 63 | $5,725 |
| Rosuvastatin Calcium Generic | 167 | 557 | 63 | $1,954 |
| Insulin Glargine-Yfgn Generic | 161 | 463 | 69 | $24K |
| Glipizide Generic | 145 | 479 | 65 | $1,893 |
| Veo Insulin Syringe Syringe-Needle,insulin,0.5 Ml | 141 | 440 | 64 | $3,566 |
| Losartan Potassium Generic | 124 | 409 | 45 | $1,585 |
| Lisinopril Generic | 108 | 360 | 43 | $1,369 |
| Amlodipine Besylate Generic | 93 | 303 | 35 | $1,115 |
| Humulin N Insulin Nph Human Isophane | 90 | 273 | 43 | $14K |
| Humulin R Insulin Regular, Human | 82 | 235 | 35 | $12K |
Brand drugs: 998 claims; generic drugs: 2,154 claims.
Money and other things of value reported by the companies
No payments from drug or medical device companies to Derek N Fong were reported in the years we have.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.